What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?

Expert Opin Pharmacother. 2021 Jul;22(10):1217-1220. doi: 10.1080/14656566.2021.1912014. Epub 2021 Apr 21.

Authors

Masato Yoneda¹, Yasushi Honda¹, Satoru Saito¹, Atsushi Nakajima¹

Affiliation

¹ Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama, Japan.

PMID: 33880982
DOI: 10.1080/14656566.2021.1912014

No abstract available

Publication types

Editorial

MeSH terms

Humans
Liver Cirrhosis
Non-alcoholic Fatty Liver Disease* / drug therapy
Risk Factors